Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Cyclophosphamide 88Rituximab 76Specimen Handling 75Magnetic Resonance Spectroscopy 64Biopsy 60Vincristine 49Doxorubicin 48Prednisone 45venetoclax 38obinutuzumab 34fludarabine 32Lenalidomide 29ibrutinib 28Cytarabine 27Dexamethasone 26Methotrexate 25prednylidene 23Etoposide 23zanubrutinib 22deltacortene 22CT-P10 22blinatumomab 21acalabrutinib 21Nivolumab 21fludarabine phosphate 19merphos 18Bendamustine Hydrochloride 17Calcium Dobesilate 16pembrolizumab 15X-Rays 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ibritumomab tiuxetan × Lymphoid × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡